New Delhi, India – 110 016

South Delhi Pharma, New Delhi, India

IMBRUVICA (ibrutinib) capsules, for oral use

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email to discuss.

Facts of Imbruvica (ibrutinib)

IMBRUVICA® (ibrutinib) capsules, for oral use
IMBRUVICA® (ibrutinib) tablets, for oral use
Initial U.S. Approval: 2013
Generic Name: ibrutinib
Company: AbbVie
Mechanism of Action: Bruton’s tyrosine kinase (BTK) inhibitor

South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Imbruvica (ibrutinib) ” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Imbruvica (ibrutinib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Categories ,
Categories ,

Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:

Query Form


What Imbruvica is?

IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with:
• Mantle cell lymphoma (MCL) who have received at least one prior therapy.
• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).
• Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.
• Waldenström’s macroglobulinemia (WM).
• Marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
• Chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy

What Ibrutinib is?

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that binds permanently to a protein, Bruton’s tyrosine kinase (BTK), that is important in B cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström’s macroglobulinemia.

Ibrutinib is used to treat chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia, and as a second-line treatment for mantle cell lymphoma, marginal zone lymphoma, and chronic graft vs host disease.

Related Products